Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction

The Methodist Hospital Research Institute (TMHRI)

Status and phase: Enrolling; Phase 4

Conditions: Anterior Cruciate Ligament Injuries; Anterior Cruciate Ligament Tear; Anterior Cruciate Ligament Rupture

Treatments: Drug: Intraosseous Morphine

Study type: Interventional

Funder types: Other

Identifiers

NCT06511232

PRO00037918

Details and patient eligibility

About

The purpose of this study is to determine if intraosseous (IO) morphine decreases pain and post-operative opioid use in patients undergoing anterior cruciate ligament (ACL) reconstruction.

Enrollment: 84 estimated patients

Sex: All

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients of the IRB approved surgeon(s) undergoing ACL reconstruction with bone-to-bone (BTB) autograft
• Patients aged between 18-40 years old at the time of surgery

Exclusion criteria

• Patients undergoing ACL reconstruction with any other type of autograft or allograft other than BTB
• Patients younger than 18 years old or older than 40 years old
• Patients undergoing meniscal root repair or any other repair that changes their weight-bearing status
• Patients with a history of substance abuse
• Vulnerable populations
• Patients on chronic pain medication within the last 6 months
• BMI >/= 35
• Allergy to morphine
• Unwilling to participate
• Any additional reason the PI deems reasonable

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

84 participants in 2 patient groups

Intraosseous Injection of Morphine

Experimental group

Description:

The intervention group will receive an intraosseous (IO) injection of 10mg of morphine mixed with up to 100mg of saline into the tibial tubercle during a standard ACL reconstruction.

Treatment:

Drug: Intraosseous Morphine

Standard of Care Morphine Administration

No Intervention group

Description:

The control group will receive the standard of care treatment, which is no IO injection during a standard ACL reconstruction.